Document Classification

Section Type: RESULTS

Text: Significantly more patients recorded improvements in HRQoL and symptoms with gefitinib in the EGFR mutation-positive subgroup (n = 259 ; FACT-L 70. 2 % versus 44. 5 % ; odds ratio, 3. 01 [95 % confidence interval, 1. 79-5. 07] ; p < 0. 001 ; TOI 70. 2 % versus 38. 3 % ; 3. 96 [2. 33-6. 71] ; p < 0. 001 ; LCS 75. 6 % versus 53. 9 % ; 2. 70 [1. 58-4. 62] ; p < 0. 001), and with carboplatin/paclitaxel in the EGFR mutation-negative subgroup (n = 169 ; FACT-L 14. 6 % versus 36. 3 % ; odds ratio, 0. 31 [0. 15-0. 65] ; p = 0. 002 ; TOI 12. 4 % versus 28. 8 % ; 0. 35 [0. 16-0. 79] ; p = 0. 011 ; LCS 20. 2 % versus 47. 5 % ; 0. 28 [0. 14-0. 55] ; p < 0. 001).